Kelly Martin said that even without selling Skelaxin, he is confident the company can raise the money it needs.

FORBES: Magazine Article

The patent under investigation is the only one listed for Skelaxin.

FORBES: Magazine Article

Elan Pharmaceuticals ' sale of the muscle relaxant Skelaxin to King Pharmaceuticals could be endangered by an investigation into the drug by the U.S. Federal Trade Commission.

FORBES: Magazine Article

The FTC is investigating one of the patents for Skelaxin listed by Elan in the U.S. Food and Drug Administration's Orange Book, a listing of drugs still protected from generic competition by patents or other regulatory mechanisms.

FORBES: Magazine Article